Table 3. Immune check point inhibitors adverse events (49).

Adverse Events (AEs)	PD-1 inhibitors (n=3,284)	PD-L1 inhibitors (n=2,615)	P value
Overall AEs (%)	72	65	0.3
Grade 3–5 AEs* (%)	22	21	0.5
Fatigue, any grade (%)	19	21	0.4
Diarrhea, any grade (%)	9	12	0.4
Rash, any grade (%)	9	7	0.8

PD-1, programmed death-1; PD-L1, programmed death-ligand 1.